<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00270257</url>
  </required_header>
  <id_info>
    <org_study_id>HPTN 058</org_study_id>
    <secondary_id>10144</secondary_id>
    <nct_id>NCT00270257</nct_id>
  </id_info>
  <brief_title>Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users</brief_title>
  <official_title>A Phase III Randomized Controlled Trial to Evaluate the Efficacy of Drug Treatment in Prevention of HIV Infection and Death Among Opiate Dependent Injectors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug abuse and HIV/AIDS are serious global health problems. Injection drug use is currently
      the major mode of transmission of HIV in many countries. The purpose of this study is to
      determine the effectiveness of drug and risk reduction counseling combined with either
      substitution drug treatment with buprenorphine/naloxone (BUP/NX) or short-term detoxification
      with BUP/NX in preventing HIV transmission among injection drug users. Participants will be
      recruited for this study in China and Thailand.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Effective HIV prevention among injection drug users (IDUs) requires educating the at-risk
      population about HIV transmission and risky behavior, and providing the means for behavior
      change. Current treatment for opiate dependence focuses on reducing the frequency of drug
      use. BUP/NX is a combination pill currently used to treat opiate-dependent individuals. This
      trial will evaluate the effectiveness of two therapies in preventing HIV transmission among
      IDUs. Drug and risk reduction counseling combined with either long term medication assisted
      treatment (LT-MAT) with BUP/NX or short term medication assisted treatment (ST-MAT) with
      BUP/NX will be compared in preventing the transmission of HIV among opiate-dependent
      individuals.

      This study will last 4.5 years. Participants in this study will be randomly assigned to one
      of two treatment arms. Group 1 will receive LT-MAT with BUP/NX. Group 2 will receive ST-MAT
      with BUP/NX. An initial 4-week safety and feasibility phase will involve the first 50
      participants at each site and will last approximately 30 weeks. Study visits will occur every
      week and will include a physical exam and blood and urine collection.

      The main treatment phase of the study will last 52 weeks. Participants in Group 1 will
      receive BUP/NX under the tongue, at first daily and then three times a week for 52 weeks.
      Participants assigned to Group 1 will take part in a BUP/NX reduction phase, which will occur
      between Weeks 47 and 52. Participants in Group 2 will receive short-term BUP/NX; dosage and
      length of treatment will be determined by the investigator. Participants assigned to Group 2
      will receive BUP/NX for a maximum of 18 days; detoxification may be repeated at Week 26 if
      the participant is still injecting opiates. After Week 4 of the safety phase and Weeks 26 and
      52 of the overall study, participants will complete an intervention acceptability assessment.

      In addition, participants in both groups will attend drug and risk reduction counseling
      weekly. After the first 12 weeks, participants will return every 4 weeks for 10 more
      counseling sessions. HIV testing, hepatitis C testing, risk assessment, and urine tests for
      opiates will occur at screening and at Weeks 26, 52, 78, 104, 130 and 156. Plasma from blood
      samples will be stored at each of these visits. Hepatitis B testing will occur at Week 26.
      Participants in China will attend study visits through approximately Week 104, and
      participants in Thailand will attend study visits through approximately Week 156.

      Participants in China who have been incarcerated may participate in an optional substudy,
      which is examining the withdrawal effects from BUP/NX after incarceration. Participants who
      agree to take part in the substudy will attend one study visit and will complete a
      questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    DSMB halted the study due to futility as a result of lower than anticipated HIV incidence rates
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of HIV-1 Infection or Death for Visits up to 104 Weeks</measure>
    <time_frame>For visits up to week 104</time_frame>
    <description>The primary endpoint for the study was cumulative HIV infection or death after a second year of follow-up (i.e. at week 104), one year after completion of the treatment phase, designed to test a durable intervention effect.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Urinalysis Results Positive for Opiates</measure>
    <time_frame>Measured through Week 104</time_frame>
    <description>Urine drug screen were assessed monthly and semiannually.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-report of Continued Injection Opiate Use in the Last 30 Days</measure>
    <time_frame>Measured through Week 104</time_frame>
    <description>All participants completed interviewer-administered assessments of injection and non-injection drug use at baseline and at semi-annual visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reported Using Injection Equipment (Needles, Syringes, Cookers, Cottons, and Rinse Water) in the Prior 6 Months</measure>
    <time_frame>Measured through Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported Number of Injections in the Last Month</measure>
    <time_frame>Measured through Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident Hepatitis C Infections for Thailand and China</measure>
    <time_frame>Measured through week 156 in Thailand and 104 weeks in China</time_frame>
    <description>HCV antibody using two different HCV EIA assays (Ortho HCV antibody version 3.0 and Wantai HCV antibody assay) at baseline and between 26-156 weeks later.
If both HCV EIA antibody assays were nonreactive, then the participant was considered not to be HCV infected. If either assay was reactive, then the Ortho HCV assay was repeated in duplicate. If two of 3 Ortho HCV assays were reactive, then the participant was considered to be HCV infected. Samples that were repeatedly reactive for HCV antibody at a follow-up visit were tested for HCV RNA by the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV assay. Not all participants had follow-up testing performed in China due to early closure of the study by the Data Safety Monitoring Board on account of futility due to a low HIV incidence (the primary study endpoint).
Analysis was done separately for both countries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident Hepatitis B Infections</measure>
    <time_frame>Measured through week 52</time_frame>
    <description>Serum samples were tested at baseline and between 26-52 weeks later for Hepatitis B surface antigen (HBsAg) using a commercial enzyme immunoassay (EIA) (Abbott Murex HBsAg version 3.0). If the HBsAg test was initially non-reactive, then the participant was considered to be negative for HBsAg. If the HBsAg test was initially reactive, then it was repeated in duplicate. If at least two of 3 tests were reactive, then the participant was considered to be positive for HBsAg.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1251</enrollment>
  <condition>HIV Infections</condition>
  <condition>Opioid-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Long term medication assisted treatment (LT-MAT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BUP/NX under the tongue daily for a maximum of three weeks(until dose stabilization) and then three times a week for 52 weeks in addition to weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Short term medication assisted treatment (ST-MAT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator.Additionally, participants will undergo weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine/Naloxone</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Long term medication assisted treatment (LT-MAT)</arm_group_label>
    <arm_group_label>Short term medication assisted treatment (ST-MAT)</arm_group_label>
    <other_name>BUP/NX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-uninfected within 28 days of enrollment

          -  Meets DSM-IV criteria for opiate dependence

          -  Positive urine test for opiates

          -  Injected opiates at least 12 times in the 28 days prior to enrollment, according to
             self-report

          -  Willing to use acceptable forms of contraception for the first 12 months of the study

          -  Able to provide contact information and willing to be contacted by study staff as
             necessary

          -  Available for study visits for at least 2 years

        Exclusion Criteria:

          -  Current treatment with methadone, morphine, levo-alpha-acetyl-methadol (LAAM),
             naltrexone, or nalmefene

          -  Currently enrolled in another HIV prevention or drug use intervention study

          -  Known sensitivity to buprenorphine or naloxone

          -  Requires immediate medical attention for dependence on alcohol, benzodiazepines, or
             other substances. People who are dependent on tobacco are not excluded.

          -  Currently injecting drugs of abuse other than opiates, more than twice in the last 28
             days, according to self-report

          -  Psychological disturbance or cognitive impairment that may interfere with the study

          -  Acute or chronic kidney failure

          -  Certain abnormal laboratory values

          -  Any other medical or psychiatric condition that, in the opinion of the investigator,
             would make participation in this study unsafe

          -  Pregnant or breastfeeding

        Inclusion Criteria for Substudy:

          -  Current or former participant in HPTN 058 study in Xinjiang who was actively in the
             long-term treatment arm on stable maintenance dose of Suboxone when detained/arrested
             (last dose within 2 days of incarceration), resulting in immediate cessation of
             Suboxone without tapering

          -  Currently released from detention

          -  Willing to complete one-time questionnaire

          -  Willing to sign informed consent

        Exclusion Criteria for Substudy:

          -  Any medical or psychiatric condition that, in the opinion of the investigator, would
             make participation in the study unsafe, or would otherwise interfere with the study
             objectives or interpretation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Metzger, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Center for Studies of Addiction, University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heng County Ctr. for Disease Control &amp; Prevention CRS</name>
      <address>
        <city>Hengzhou Town</city>
        <state>Guangxi</state>
        <zip>530300</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangxi Ctrs. for Disease Control &amp; Prevention and for HIV/AIDS Prevention &amp; Control CRS</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530028</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xinjiang CRS</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMU HIV Prevention CRS</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Aceijas C, Stimson GV, Hickman M, Rhodes T; United Nations Reference Group on HIV/AIDS Prevention and Care among IDU in Developing and Transitional Countries. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS. 2004 Nov 19;18(17):2295-303.</citation>
    <PMID>15577542</PMID>
  </reference>
  <reference>
    <citation>Gowing L, Farrell M, Bornemann R, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004145. Review. Update in: Cochrane Database Syst Rev. 2008;(2):CD004145.</citation>
    <PMID>15495080</PMID>
  </reference>
  <reference>
    <citation>Koester S, Glanz J, Barón A. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. AIDS Behav. 2005 Mar;9(1):27-39.</citation>
    <PMID>15812611</PMID>
  </reference>
  <reference>
    <citation>Raisch DW, Fye CL, Boardman KD, Sather MR. Opioid dependence treatment, including buprenorphine/naloxone. Ann Pharmacother. 2002 Feb;36(2):312-21. Review.</citation>
    <PMID>11847954</PMID>
  </reference>
  <reference>
    <citation>Ruan Y, Qin G, Liu S, Qian H, Zhang L, Zhou F, He Y, Chen K, Yin L, Chen X, Hao Q, Xing H, Song Y, Wang Y, Hong K, Chen J, Shao Y. HIV incidence and factors contributed to retention in a 12-month follow-up study of injection drug users in Sichuan Province, China. J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):459-63.</citation>
    <PMID>16010170</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2005</study_first_submitted>
  <study_first_submitted_qc>December 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2005</study_first_posted>
  <results_first_submitted>November 5, 2015</results_first_submitted>
  <results_first_submitted_qc>October 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 8, 2016</results_first_posted>
  <last_update_submitted>December 8, 2016</last_update_submitted>
  <last_update_submitted_qc>December 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Seronegativity</keyword>
  <keyword>Opiate Addiction</keyword>
  <keyword>Opiate Dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The sites were selected based on prior HIV incidence rates among opiate injectors.
At the first scheduled interim analyses, when 25% of the participants had completed 104 weeks on study, the Data Safety Monitoring Board (DSMB) halted the study due to futility as a result of lower than anticipated HIV incidence rates.</recruitment_details>
      <pre_assignment_details>The study represented the first use of buprenorphine-naloxone as a treatment for opiate dependence in each community, thus implementation of the study and recruitment of participants included a significant effort devoted to community engagement and education. Each site had an active community advisory board (CAB).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Long Term Medication Assisted Treatment (LT-MAT)</title>
          <description>Participants will receive BUP/NX under the tongue daily for a maximum of three weeks(until dose stabilization) and then three times a week for 52 weeks in addition to weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52
Buprenorphine/Naloxone: Oral tablet</description>
        </group>
        <group group_id="P2">
          <title>Short Term Medication Assisted Treatment (ST-MAT)</title>
          <description>Participants will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator.Additionally, participants will undergo weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52.
Buprenorphine/Naloxone: Oral tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="623"/>
                <participants group_id="P2" count="628">1 excluded from analysis (enrollment date exceeded eligibility window by 13 days)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 8</title>
              <participants_list>
                <participants group_id="P1" count="510"/>
                <participants group_id="P2" count="443"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 26</title>
              <participants_list>
                <participants group_id="P1" count="460"/>
                <participants group_id="P2" count="440"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 52</title>
              <participants_list>
                <participants group_id="P1" count="362"/>
                <participants group_id="P2" count="340"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 78</title>
              <participants_list>
                <participants group_id="P1" count="283"/>
                <participants group_id="P2" count="285"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 104</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
                <participants group_id="P2" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
                <participants group_id="P2" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="412"/>
                <participants group_id="P2" count="424"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Data Safety Monitoring Board (DSMB) halt</title>
              <participants_list>
                <participants group_id="P1" count="412"/>
                <participants group_id="P2" count="424"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Long Term Medication Assisted Treatment (LT-MAT)</title>
          <description>Participants will receive BUP/NX under the tongue daily for a maximum of three weeks(until dose stabilization) and then three times a week for 52 weeks in addition to weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52
Buprenorphine/Naloxone: Oral tablet</description>
        </group>
        <group group_id="B2">
          <title>Short Term Medication Assisted Treatment (ST-MAT)</title>
          <description>Participants will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator.Additionally, participants will undergo weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52.
Buprenorphine/Naloxone: Oral tablet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="623"/>
            <count group_id="B2" value="627"/>
            <count group_id="B3" value="1250"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="27" upper_limit="39"/>
                    <measurement group_id="B2" value="34" lower_limit="28" upper_limit="39"/>
                    <measurement group_id="B3" value="34" lower_limit="28" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="574"/>
                    <measurement group_id="B2" value="577"/>
                    <measurement group_id="B3" value="1151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="522"/>
                    <measurement group_id="B2" value="527"/>
                    <measurement group_id="B3" value="1049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years of Injection</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="3" upper_limit="12"/>
                    <measurement group_id="B2" value="7" lower_limit="3" upper_limit="12"/>
                    <measurement group_id="B3" value="7" lower_limit="3" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evidence of HIV-1 Infection or Death for Visits up to 104 Weeks</title>
        <description>The primary endpoint for the study was cumulative HIV infection or death after a second year of follow-up (i.e. at week 104), one year after completion of the treatment phase, designed to test a durable intervention effect.</description>
        <time_frame>For visits up to week 104</time_frame>
        <population>Data Safety Monitoring Board (DSMB) halted the study on October 4, 2011 due to futility as a result of lower than anticipated HIV incidence rates. See participant flow section for the number of participants who completed visit up to 104 by July 31, 2012.</population>
        <group_list>
          <group group_id="O1">
            <title>Long Term Medication Assisted Treatment (LT-MAT)</title>
            <description>Participants will receive BUP/NX under the tongue daily for a maximum of three weeks(until dose stabilization) and then three times a week for 52 weeks in addition to weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52
Buprenorphine/Naloxone: Oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Short Term Medication Assisted Treatment (ST-MAT)</title>
            <description>Participants will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator.Additionally, participants will undergo weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52.
Buprenorphine/Naloxone: Oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Evidence of HIV-1 Infection or Death for Visits up to 104 Weeks</title>
          <description>The primary endpoint for the study was cumulative HIV infection or death after a second year of follow-up (i.e. at week 104), one year after completion of the treatment phase, designed to test a durable intervention effect.</description>
          <population>Data Safety Monitoring Board (DSMB) halted the study on October 4, 2011 due to futility as a result of lower than anticipated HIV incidence rates. See participant flow section for the number of participants who completed visit up to 104 by July 31, 2012.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="470"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># of HIV infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incident rate per 100 person-years</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incident rate per 100 person-years</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3769</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.694</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.308</ci_lower_limit>
            <ci_upper_limit>1.562</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Urinalysis Results Positive for Opiates</title>
        <description>Urine drug screen were assessed monthly and semiannually.</description>
        <time_frame>Measured through Week 104</time_frame>
        <population>Number of participants presented here applies to visit 104 for whom data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Long Term Medication Assisted Treatment (LT-MAT)</title>
            <description>Participants will receive BUP/NX under the tongue daily for a maximum of three weeks(until dose stabilization) and then three times a week for 52 weeks in addition to weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52
Buprenorphine/Naloxone: Oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Short Term Medication Assisted Treatment (ST-MAT)</title>
            <description>Participants will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator.Additionally, participants will undergo weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52.
Buprenorphine/Naloxone: Oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Urinalysis Results Positive for Opiates</title>
          <description>Urine drug screen were assessed monthly and semiannually.</description>
          <population>Number of participants presented here applies to visit 104 for whom data available.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4325</p_value>
            <p_value_desc>P value applies for the comparison at visit 104.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>adjusted for site</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.844</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.553</ci_lower_limit>
            <ci_upper_limit>1.289</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-report of Continued Injection Opiate Use in the Last 30 Days</title>
        <description>All participants completed interviewer-administered assessments of injection and non-injection drug use at baseline and at semi-annual visits.</description>
        <time_frame>Measured through Week 104</time_frame>
        <population>Number of participants presented here applies to whom data available at week 104.</population>
        <group_list>
          <group group_id="O1">
            <title>Long Term Medication Assisted Treatment (LT-MAT)</title>
            <description>Participants will receive BUP/NX under the tongue daily for a maximum of three weeks(until dose stabilization) and then three times a week for 52 weeks in addition to weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52
Buprenorphine/Naloxone: Oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Short Term Medication Assisted Treatment (ST-MAT)</title>
            <description>Participants will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator.Additionally, participants will undergo weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52.
Buprenorphine/Naloxone: Oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Self-report of Continued Injection Opiate Use in the Last 30 Days</title>
          <description>All participants completed interviewer-administered assessments of injection and non-injection drug use at baseline and at semi-annual visits.</description>
          <population>Number of participants presented here applies to whom data available at week 104.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2749</p_value>
            <p_value_desc>P value applies for the comparison at visit 104 only.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.800</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.536</ci_lower_limit>
            <ci_upper_limit>1.194</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reported Using Injection Equipment (Needles, Syringes, Cookers, Cottons, and Rinse Water) in the Prior 6 Months</title>
        <time_frame>Measured through Week 104</time_frame>
        <population>Number of participants presented here applies to whom data available at week 104.</population>
        <group_list>
          <group group_id="O1">
            <title>Long Term Medication Assisted Treatment (LT-MAT)</title>
            <description>Participants will receive BUP/NX under the tongue daily for a maximum of three weeks(until dose stabilization) and then three times a week for 52 weeks in addition to weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52
Buprenorphine/Naloxone: Oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Short Term Medication Assisted Treatment (ST-MAT)</title>
            <description>Participants will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator.Additionally, participants will undergo weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52.
Buprenorphine/Naloxone: Oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reported Using Injection Equipment (Needles, Syringes, Cookers, Cottons, and Rinse Water) in the Prior 6 Months</title>
          <population>Number of participants presented here applies to whom data available at week 104.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3446</p_value>
            <p_value_desc>Analysis is done for visit 104</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Adjusted for site</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.746</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.407</ci_lower_limit>
            <ci_upper_limit>1.369</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-reported Number of Injections in the Last Month</title>
        <time_frame>Measured through Week 104</time_frame>
        <population>Number of participants presented here applies to whom data available at week 104.</population>
        <group_list>
          <group group_id="O1">
            <title>Long Term Medication Assisted Treatment (LT-MAT)</title>
            <description>Participants will receive BUP/NX under the tongue daily for a maximum of three weeks(until dose stabilization) and then three times a week for 52 weeks in addition to weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52
Buprenorphine/Naloxone: Oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Short Term Medication Assisted Treatment (ST-MAT)</title>
            <description>Participants will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator.Additionally, participants will undergo weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52.
Buprenorphine/Naloxone: Oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Self-reported Number of Injections in the Last Month</title>
          <population>Number of participants presented here applies to whom data available at week 104.</population>
          <units>injections</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="623"/>
                <count group_id="O2" value="627"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="6" upper_limit="60"/>
                    <measurement group_id="O2" value="30" lower_limit="7" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3620</p_value>
            <p_value_desc>P value applies for the comparison at visit 104 only. See the estimation comments for the other visits</p_value_desc>
            <method>Generalized linear model</method>
            <method_desc>adjusted for site.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.8712</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6477</ci_lower_limit>
            <ci_upper_limit>1.1718</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incident Hepatitis C Infections for Thailand and China</title>
        <description>HCV antibody using two different HCV EIA assays (Ortho HCV antibody version 3.0 and Wantai HCV antibody assay) at baseline and between 26-156 weeks later.
If both HCV EIA antibody assays were nonreactive, then the participant was considered not to be HCV infected. If either assay was reactive, then the Ortho HCV assay was repeated in duplicate. If two of 3 Ortho HCV assays were reactive, then the participant was considered to be HCV infected. Samples that were repeatedly reactive for HCV antibody at a follow-up visit were tested for HCV RNA by the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV assay. Not all participants had follow-up testing performed in China due to early closure of the study by the Data Safety Monitoring Board on account of futility due to a low HIV incidence (the primary study endpoint).
Analysis was done separately for both countries</description>
        <time_frame>Measured through week 156 in Thailand and 104 weeks in China</time_frame>
        <population>Baseline HCV antibody negative participants.</population>
        <group_list>
          <group group_id="O1">
            <title>China</title>
            <description>Long Term and Short arms were compared</description>
          </group>
          <group group_id="O2">
            <title>Thailand</title>
            <description>Long Term and Short arms were compared</description>
          </group>
        </group_list>
        <measure>
          <title>Incident Hepatitis C Infections for Thailand and China</title>
          <description>HCV antibody using two different HCV EIA assays (Ortho HCV antibody version 3.0 and Wantai HCV antibody assay) at baseline and between 26-156 weeks later.
If both HCV EIA antibody assays were nonreactive, then the participant was considered not to be HCV infected. If either assay was reactive, then the Ortho HCV assay was repeated in duplicate. If two of 3 Ortho HCV assays were reactive, then the participant was considered to be HCV infected. Samples that were repeatedly reactive for HCV antibody at a follow-up visit were tested for HCV RNA by the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV assay. Not all participants had follow-up testing performed in China due to early closure of the study by the Data Safety Monitoring Board on account of futility due to a low HIV incidence (the primary study endpoint).
Analysis was done separately for both countries</description>
          <population>Baseline HCV antibody negative participants.</population>
          <units>participants with HCV antibody</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incident rate of 100 person-years</param_type>
            <param_value>22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.7</ci_lower_limit>
            <ci_upper_limit>31.6</ci_upper_limit>
            <estimate_desc>29 events over 132 person-years</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incident rate of 100 person-years</param_type>
            <param_value>4.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.0</ci_lower_limit>
            <ci_upper_limit>9.0</ci_upper_limit>
            <estimate_desc>8 events over 174 person-years</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incident Hepatitis B Infections</title>
        <description>Serum samples were tested at baseline and between 26-52 weeks later for Hepatitis B surface antigen (HBsAg) using a commercial enzyme immunoassay (EIA) (Abbott Murex HBsAg version 3.0). If the HBsAg test was initially non-reactive, then the participant was considered to be negative for HBsAg. If the HBsAg test was initially reactive, then it was repeated in duplicate. If at least two of 3 tests were reactive, then the participant was considered to be positive for HBsAg.</description>
        <time_frame>Measured through week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>China</title>
            <description>Long Term and Short arms were compared</description>
          </group>
          <group group_id="O2">
            <title>Thailand</title>
            <description>Long Term and Short arms were compared</description>
          </group>
        </group_list>
        <measure>
          <title>Incident Hepatitis B Infections</title>
          <description>Serum samples were tested at baseline and between 26-52 weeks later for Hepatitis B surface antigen (HBsAg) using a commercial enzyme immunoassay (EIA) (Abbott Murex HBsAg version 3.0). If the HBsAg test was initially non-reactive, then the participant was considered to be negative for HBsAg. If the HBsAg test was initially reactive, then it was repeated in duplicate. If at least two of 3 tests were reactive, then the participant was considered to be positive for HBsAg.</description>
          <units>participants with HBsAg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="607"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incident rate of 100 person-years</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.22</ci_lower_limit>
            <ci_upper_limit>5.08</ci_upper_limit>
            <estimate_desc>9 events over 336 person-years</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incident rate of 100 person-years</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
            <estimate_desc>0 events over 37 person-years</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Long Term Medication Assisted Treatment (LT-MAT)</title>
          <description>Participants will receive BUP/NX under the tongue daily for a maximum of three weeks(until dose stabilization) and then three times a week for 52 weeks in addition to weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52
Buprenorphine/Naloxone: Oral tablet</description>
        </group>
        <group group_id="E2">
          <title>Short Term Medication Assisted Treatment (ST-MAT)</title>
          <description>Participants will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator.Additionally, participants will undergo weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52.
Buprenorphine/Naloxone: Oral tablet</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="623"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Bone tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Neurocysticercosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Penicilliosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage traumatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="623"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="623"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Personality disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Henoch−Schonlein purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="623"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>chest Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="623"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All study abstracts and publications are subject to HPTN Publication and Public Information Policies and Clinical Trial Agreements between NIAID (DAIDS) and company collaborators. The publication or other disclosure can be delayed for up to thirty additional business days for manuscripts &amp; five business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Statistical Analyst</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>206-667-6167</phone>
      <email>geetha@scharp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

